PHOENIX Pharma Belgium

{
  "events": [
    {
      "kind": "director_out",
      "role": "commissaire",
      "person": {
        "rrn": null,
        "name": "Deloitte Bedrijfsrevisoren/R\u00E9viseurs d\u0027entreprises BV SRL",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "commissaire",
      "person": {
        "rrn": null,
        "name": "Forvis Mazars R\u00E9viseurs d\u0027Entreprises SRL/Bedrijfsrevisoren BV",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "commissaire (repr\u00E9sentant)",
      "person": {
        "rrn": null,
        "name": "Thomas Verhamme",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "PHOENIX Pharma Belgium"
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Deloitte Bedrijfsrevisoren/R\u00E9viseurs d\u0027entreprises BV SRL",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Forvis Mazars R\u00E9viseurs d\u0027Entreprises SRL/Bedrijfsrevisoren BV",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Thomas Verhamme",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "PHOENIX Pharma Belgium"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "PHOENIX Pharma Belgium",
    "old": "PHARMA BELGIUM - BELMEDIS",
    "changed": true
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": false
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "PHOENIX Pharma Belgium"
  },
  "legal_form_change": {
    "new": "Soci\u00E9t\u00E9 anonyme",
    "old": "Soci\u00E9t\u00E9 anonyme",
    "changed": false
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "PHOENIX Pharma Belgium",
    "old": "PHARMA BELGIUM - BELMEDIS",
    "changed": true
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": false
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "PHARMA BELGIUM - BELMEDIS"
  },
  "legal_form_change": {
    "new": "Soci\u00E9t\u00E9 anonyme",
    "old": "Soci\u00E9t\u00E9 anonyme",
    "changed": false
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Philippe Lacroix",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "commissaire aux comptes",
      "person": {
        "rrn": null,
        "name": "Julie Delforge",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "Pharma Belgium-Belmedis"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Philippe Lacroix",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Deloitte Bedrijfsrevisoren/R\u00E9viseurs d\u0027Entreprises BV SRL",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Julie Delforge",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "Pharma Belgium-Belmedis NV"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "",
    "old": "",
    "changed": false
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": false
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "PHARMA BELGIUM - BELMEDIS"
  },
  "legal_form_change": {
    "new": "",
    "old": "Soci\u00E9t\u00E9 anonyme",
    "changed": false
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "",
    "old": "",
    "changed": false
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": false
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "PHARMA BELGIUM - BELMEDIS"
  },
  "legal_form_change": {
    "new": "Soci\u00E9t\u00E9 anonyme",
    "old": "Soci\u00E9t\u00E9 anonyme",
    "changed": false
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Arnaud Berken",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Hubert Olivier",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "Pharma Belgium-Belmedis NV"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Arnaud Berken",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_out",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Hubert Olivier",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "Pharma Belgium-Belmedis"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "",
    "old": "",
    "changed": false
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": false
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "PHARMA BELGIUM - BELMEDIS"
  },
  "legal_form_change": {
    "new": "",
    "old": "Soci\u00E9t\u00E9 anonyme",
    "changed": false
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "",
    "old": "",
    "changed": false
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": false
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "PHARMA BELGIUM - BELMEDIS"
  },
  "legal_form_change": {
    "new": "",
    "old": "Soci\u00E9t\u00E9 anonyme",
    "changed": false
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Hubert Olivier",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "Pharma Belgium-Belmedis"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "administrator",
      "person": {
        "rrn": null,
        "name": "Philippe Lacroix",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "administrator",
      "person": {
        "rrn": null,
        "name": "Hubert Olivier",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "commissaire",
      "person": {
        "rrn": null,
        "name": "Julie Delforge",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "Pharma Belgium-Belmedis"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Philippe Lacroix",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Hubert Olivier",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Deloitte Bedrijfsrevisoren/R\u00E9viseurs d\u0027entreprises SC SCRL",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Julie Delforge",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "Pharma Belgium-Belmedis NV"
  }
}

{
  "stage": null,
  "notary": {
    "name": "Daisy DEKEGEL",
    "firm_city": null,
    "firm_name": "Berquin Notaires",
    "office_city": "Bruxelles",
    "is_associated": true
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2021-10-25",
    "filing_date": "2021-02-26",
    "act_kind_objet": "ASSEMBLEE GENERALE EXTRAORDINAIRE RECTIFICATIVE"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2021-09-17",
    "unanimous": null
  },
  "conversion": null,
  "detected_kind": "material_correction",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0425.353.116",
        "name": "Pharma Belgium - Belmedis",
        "role": "acquiring",
        "address": "1200 Woluwe-Saint-Lambert, Avenue Emile Vandervelde 82",
        "is_foreign": false,
        "legal_form": "SA",
        "is_new_company": false,
        "jurisdiction_country": null
      },
      {
        "kbo": "0405.605.894",
        "name": "Laboratoria Flandria",
        "role": "absorbed",
        "address": "1300 Wavre, Avenue Pasteur 2",
        "is_foreign": false,
        "legal_form": "SA",
        "is_new_company": false,
        "jurisdiction_country": null
      }
    ],
    "exchange_ratio": null,
    "legal_articles": [
      "12:7",
      "12:50",
      "12:75",
      "7:179",
      "7:197"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": "2021-02-28",
    "exchange_ratio_text": null,
    "new_shares_issued_n": 5392347,
    "real_estate_included": false,
    "patrimony_description": "La totalit\u00E9 du patrimoine de la Soci\u00E9t\u00E9 Absorb\u00E9e est transf\u00E9r\u00E9e \u00E0 titre universel \u00E0 la Soci\u00E9t\u00E9 Absorbante. Le transfert concerne l\u0027ensemble du patrimoine sans exception ni r\u00E9serve.",
    "equity_transferred_eur": 5094300.0,
    "accounting_effective_date": "2021-03-01"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "Pharma Belgium - Belmedis",
    "legal_form": "SA"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Daisy DEKEGEL",
    "org_rep_person_name": null
  },
  "summary_narrative": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire de Pharma Belgium - Belmedis, tenue le 17 septembre 2021, a d\u00E9cid\u00E9 de corriger une erreur mat\u00E9rielle survenue dans les proc\u00E8s-verbaux des assembl\u00E9es du 26 f\u00E9vrier 2021, concernant l\u0027identit\u00E9 des actionnaires uniques des soci\u00E9t\u00E9s absorb\u00E9e (Laboratoria Flandria) et absorbante (Pharma Belgium - Belmedis). Les r\u00E9f\u00E9rences erron\u00E9es \u00E0 la soci\u00E9t\u00E9 \u0027O.C.P.\u0027 ont \u00E9t\u00E9 rectifi\u00E9es en faveur de \u0027McKesson Belgium Holdings\u0027. Cette correction concerne les actes de fusion par absorption et les attributions de nouvelles actions.",
  "co_filed_documents": [
    "une exp\u00E9dition du proc\u00E8s-verbal",
    "une procuration",
    "le rapport compl\u00E9mentaire de l\u0027organe d\u0027administration de la Soci\u00E9t\u00E9 Absorbante en date du 10 septembre 2021",
    "le texte coordonn\u00E9 des statuts"
  ],
  "detected_real_type": "material_correction",
  "referenced_correction": {
    "prior_pub_date": "2021-03-23",
    "what_corrected": "Correction de l\u0027identit\u00E9 de l\u0027actionnaire unique de la Soci\u00E9t\u00E9 Absorb\u00E9e (remplacement de \u0027O.C.P.\u0027 par \u0027McKesson Belgium Holdings\u0027) et de la Soci\u00E9t\u00E9 Absorbante (remplacement de \u0027O.C.P.\u0027 par \u0027McKesson Belgium Holdings\u0027)",
    "prior_pub_number": "21036376"
  },
  "should_reroute_to_category": null
}

{
  "events": [],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "Pharma Belgium - Belmedis"
  }
}

{
  "stage": "completed",
  "notary": {
    "name": "Daisy DEKEGEL",
    "firm_city": null,
    "firm_name": "Berquin Notaires",
    "office_city": "Bruxelles",
    "is_associated": true
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2021-03-23",
    "filing_date": "2021-01-14",
    "act_kind_objet": "FUSION PAR ABSORPTION DE \u0022LABORATORIA FLANDRIA\u0022 SA -"
  },
  "decision": {
    "body": "bijzondere_algemene_vergadering",
    "act_date": "2021-02-26",
    "unanimous": true
  },
  "conversion": null,
  "detected_kind": "merger_absorption",
  "report_waiver": {
    "summary": "L\u0027actionnaire unique de la soci\u00E9t\u00E9 absorbante a renonc\u00E9 \u00E0 l\u0027\u00E9tablissement du rapport de l\u0027organe d\u0027administration et du rapport du commissaire sur le projet de fusion, conform\u00E9ment aux articles 12:25 et 12:26 du Code des soci\u00E9t\u00E9s et des associations.",
    "articles": [
      "5:121",
      "12:26 \u00A71"
    ]
  },
  "restructuring": {
    "parties": [
      {
        "kbo": "0425.353.116",
        "name": "Pharma Belgium - Belmedis",
        "role": "acquiring",
        "address": "1200 Woluwe-Saint-Lambert, Avenue Emile Vandervelde 82",
        "is_foreign": false,
        "legal_form": "SA",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      },
      {
        "kbo": "0405.605.894",
        "name": "Laboratoria Flandria",
        "role": "absorbed",
        "address": "1300 Wavre, Avenue Pasteur 2",
        "is_foreign": false,
        "legal_form": "SA",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      }
    ],
    "exchange_ratio": 67.15,
    "legal_articles": [
      "12:24",
      "12:25",
      "12:26",
      "7:179",
      "7:197"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": "2021-02-28",
    "exchange_ratio_text": "67,15 actions de la Soci\u00E9t\u00E9 Absorbante seront \u00E9mises pour chaque action de la Soci\u00E9t\u00E9 Absorb\u00E9e",
    "new_shares_issued_n": 5392347,
    "real_estate_included": false,
    "patrimony_description": "Le patrimoine entier de la soci\u00E9t\u00E9 absorb\u00E9e, sans exception ni r\u00E9serve, est transf\u00E9r\u00E9 \u00E0 titre universel \u00E0 la soci\u00E9t\u00E9 absorbante. L\u0027apport en nature concerne l\u0027ensemble des actifs et passifs de Laboratoria Flandria SA, \u00E9valu\u00E9s sur la base de leur valeur comptable au 31 mars 2020.",
    "equity_transferred_eur": 16344832.0,
    "accounting_effective_date": "2021-03-01"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "Pharma Belgium - Belmedis",
    "legal_form": "SA"
  },
  "publication_proxy": {
    "kind": "org",
    "org_kbo": null,
    "org_name": "AD-Ministerie",
    "person_name": null,
    "org_rep_person_name": "Adriaan De Leeuw"
  },
  "summary_narrative": "La soci\u00E9t\u00E9 anonyme Pharma Belgium - Belmedis a d\u00E9cid\u00E9 de fusionner par absorption avec la soci\u00E9t\u00E9 anonyme Laboratoria Flandria, en vue de transf\u00E9rer l\u0027int\u00E9gralit\u00E9 de son patrimoine \u00E0 titre universel. L\u0027op\u00E9ration a \u00E9t\u00E9 approuv\u00E9e par l\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire, qui a \u00E9galement d\u00E9cid\u00E9 d\u0027augmenter le capital de la soci\u00E9t\u00E9 absorbante par l\u0027\u00E9mission de 5 392 347 nouvelles actions, attribu\u00E9es en contrepartie des actions d\u00E9tenues par l\u0027actionnaire unique de Laboratoria Flandria. Le rapport du commissaire a \u00E9t\u00E9 \u00E9tabli conform\u00E9ment aux articles 7:179 et 7:197 du Code des soci\u00E9t\u00E9s et des associa",
  "co_filed_documents": [
    "une exp\u00E9dition du proc\u00E8s-verbal",
    "une procuration",
    "le rapport de l\u0027organe de gestion \u00E9tabli en application des articles 7:179, \u00A71, premier alin\u00E9a et 7:197, \u00A71, premier alin\u00E9a du Code des soci\u00E9t\u00E9s et des associations",
    "le rapport du commissaire Absorbante \u00E9tabli en application des articles 7:179, \u00A71, deuxi\u00E8me alin\u00E9a et 7:197, \u00A71, deuxi\u00E8me alin\u00E9a du Code des soci\u00E9t\u00E9s et des associations",
    "le texte coordonn\u00E9 des statuts"
  ],
  "detected_real_type": "fusion_completed",
  "referenced_correction": null,
  "should_reroute_to_category": null
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 16902300.0,
      "delta_eur": 5094300.0,
      "before_eur": 11808000.0,
      "contribution_type": "geld"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "Pharma Belgium - Belmedis"
  }
}

{
  "stage": "proposal",
  "notary": {
    "name": "Daisy Dekegel",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2021-01-22",
    "filing_date": "2021-01-12",
    "act_kind_objet": "PROJET DE FUSION ETABLI CONFORMEMENT AUX ARTICLES 12:2 ET"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2021-01-12",
    "unanimous": null
  },
  "conversion": null,
  "detected_kind": "merger_absorption",
  "report_waiver": {
    "summary": "Les actionnaires des soci\u00E9t\u00E9s appel\u00E9es \u00E0 fusionner ont renonc\u00E9 \u00E0 la r\u00E9daction d\u2019un rapport \u00E9crit par les commissaires, conform\u00E9ment \u00E0 l\u0027article 12:26 \u00A71 du Code des soci\u00E9t\u00E9s et des associations.",
    "articles": [
      "12:26 \u00A71",
      "7:179",
      "7:197"
    ]
  },
  "restructuring": {
    "parties": [
      {
        "kbo": "0425.353.116",
        "name": "Pharma Belgium-Belmedis SA",
        "role": "acquiring",
        "address": "Avenue Emile Vandervelde 82, 1200 Woluwe-Saint-Lambert, Belgique",
        "is_foreign": false,
        "legal_form": "SA",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      },
      {
        "kbo": "0405.605.894",
        "name": "Laboratoria Flandria SA",
        "role": "absorbed",
        "address": "Avenue Pasteur 2, 1300 Wavre, Belgique",
        "is_foreign": false,
        "legal_form": "SA",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      },
      {
        "kbo": "0653.962.122",
        "name": "McKesson Belgium Holdings SRL",
        "role": "other",
        "address": "Avenue Pasteur 2, 1300 Wavre, Belgique",
        "is_foreign": false,
        "legal_form": "SRL",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      },
      {
        "kbo": "0403.085.181",
        "name": "P.C.B. SA",
        "role": "other",
        "address": "Avenue Pasteur 2, 1300 Wavre, Belgique",
        "is_foreign": false,
        "legal_form": "SA",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      },
      {
        "kbo": "0441.835.592",
        "name": "Pharma Partners SRL",
        "role": "other",
        "address": "Avenue Pasteur 2, 1300 Wavre, Belgique",
        "is_foreign": false,
        "legal_form": "SRL",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      }
    ],
    "exchange_ratio": 67.15,
    "legal_articles": [
      "12:2",
      "12:24",
      "12:26 \u00A71",
      "7:179",
      "7:197"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": "2021-02-28",
    "exchange_ratio_text": "67,15 actions de Pharma Belgium-Belmedis SA pour chaque action de Laboratoria Flandria SA",
    "new_shares_issued_n": 5392347,
    "real_estate_included": false,
    "patrimony_description": "L\u0027op\u00E9ration pr\u00E9voit le transfert int\u00E9gral du patrimoine actif et passif de Laboratoria Flandria SA \u00E0 Pharma Belgium-Belmedis SA, incluant tous les actifs, passifs, droits et obligations. Le transfert s\u0027effectue sur la base des comptes arr\u00EAt\u00E9s au 28 f\u00E9vrier 2021.",
    "equity_transferred_eur": 16344831.0,
    "accounting_effective_date": "2021-03-01"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "Pharma Belgium-Belmedis SA",
    "legal_form": "SA"
  },
  "publication_proxy": {
    "kind": "org",
    "org_kbo": "0653.962.122",
    "org_name": "Ad-Ministerie SRL",
    "person_name": null,
    "org_rep_person_name": "Adriaan de Leeuw"
  },
  "summary_narrative": "Ce document est un projet de fusion par absorption, \u00E9tabli conform\u00E9ment aux articles 12:2 et 12:24 du Code des soci\u00E9t\u00E9s et des associations. Il pr\u00E9voit l\u0027absorption de Laboratoria Flandria SA par Pharma Belgium-Belmedis SA, avec un rapport d\u0027\u00E9change de 67,15 actions de la soci\u00E9t\u00E9 absorbante pour chaque action de la soci\u00E9t\u00E9 absorb\u00E9e. Le transfert du patrimoine s\u0027effectuera sur la base des comptes arr\u00EAt\u00E9s au 28 f\u00E9vrier 2021. L\u0027op\u00E9ration fait partie d\u0027une restructuration globale du groupe McKesson Belgium, visant \u00E0 simplifier sa structure juridique.",
  "co_filed_documents": [],
  "detected_real_type": "fusion_proposal",
  "referenced_correction": null,
  "should_reroute_to_category": null
}

{
  "stage": "proposal",
  "notary": {
    "name": "Daisy Dekegel",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Brussel",
    "is_associated": false
  },
  "act_meta": {
    "language": "nl",
    "pub_date": "2021-01-22",
    "filing_date": null,
    "act_kind_objet": "FUSIEVOORSTEL OPGEMAAKT OVEREENKOMSTIG DE ARTIKELEN 12:2"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2021-01-11",
    "unanimous": null
  },
  "conversion": null,
  "detected_kind": "merger_absorption",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0425.353.116",
        "name": "Pharma Belgium-Belmedis NV",
        "role": "acquiring",
        "address": "Emile Vanderveldelaan 82, 1200 Sint-Lambrechts-Woluwe, Belgi\u00EB",
        "is_foreign": false,
        "legal_form": "NV",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      },
      {
        "kbo": "0405.605.894",
        "name": "Laboratoria Flandria NV",
        "role": "absorbed",
        "address": "avenue Pasteur 2, 1300 Waver",
        "is_foreign": false,
        "legal_form": "NV",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      }
    ],
    "exchange_ratio": 67.15,
    "legal_articles": [
      "12:2",
      "12:24"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": "2021-02-28",
    "exchange_ratio_text": "67,15 aandelen van Pharma Belgium-Belmedis NV per aandeel van Laboratoria Flandria NV",
    "new_shares_issued_n": 5392347,
    "real_estate_included": false,
    "patrimony_description": "Het gehele vermogen, zowel de rechten als de verplichtingen, van Laboratoria Flandria NV wordt overgedragen aan Pharma Belgium-Belmedis NV.",
    "equity_transferred_eur": 16344831.0,
    "accounting_effective_date": "2021-03-01"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "Pharma Belgium-Belmedis",
    "legal_form": "NV"
  },
  "publication_proxy": {
    "kind": "org",
    "org_kbo": "0653.962.122",
    "org_name": "Ad-Ministerie BV",
    "person_name": null,
    "org_rep_person_name": "Adriaan de Leeuw"
  },
  "summary_narrative": "Pharma Belgium-Belmedis NV en Laboratoria Flandria NV zijn beide onderdeel van de McKesson Belgium groep. Het fusievoorstel, opgesteld overeenkomstig artikelen 12:2 en 12:24 van het Wetboek van Vennootschappen en Verenigingen, voorziet in een fusie door overneming waarbij Laboratoria Flandria NV wordt overgenomen door Pharma Belgium-Belmedis NV. De ruilverhouding is vastgesteld op 67,15 nieuwe aandelen van Pharma Belgium-Belmedis NV per aandeel van Laboratoria Flandria NV, gebaseerd op de nettoactiefwaarde per 31 maart 2020. De fusie is onderdeel van een grootschalige herstructurering binnen d",
  "co_filed_documents": [],
  "detected_real_type": "fusion_proposal",
  "referenced_correction": null,
  "should_reroute_to_category": null
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Alain Charlier",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Arnaud Berken",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_out",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Jean-Michel Cambounet",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_out",
      "role": "repr\u00E9sentant permanent du commissaire",
      "person": {
        "rrn": null,
        "name": "Eric Nys",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "repr\u00E9sentant permanent du commissaire",
      "person": {
        "rrn": null,
        "name": "Julie Delforge",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "Pharma Belgium-Belmedis"
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Alain Charlier",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Arnaud Berken",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Jean-Michel Cambounet",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "vertegenwoordiger van de commissaris",
      "person": {
        "rrn": null,
        "name": "Julie Delforge",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "Pharma Belgium-Belmedis NV"
  }
}

{
  "events": [],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "Pharma Belgium-Belmedis"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "administrateur-d\u00E9l\u00E9gu\u00E9",
      "person": {
        "rrn": null,
        "name": "Philippe Lacroix",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Hubert Olivier",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Alain Charlier",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "commissaire",
      "person": {
        "rrn": null,
        "name": "Eric Nys",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "administrateur-d\u00E9l\u00E9gu\u00E9",
      "person": {
        "rrn": null,
        "name": "Jean-Michel Cambounet",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "Pharma Belgium-Belmedis"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 11808000,
      "delta_eur": 6850000,
      "before_eur": 4958000,
      "contribution_type": "geld"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "PHARMA BELGIUM"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 11808000,
      "delta_eur": 6850000,
      "before_eur": 4958000,
      "contribution_type": "geld"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "PHARMA BELGIUM"
  }
}

{
  "stage": "proposal",
  "notary": {
    "name": "Philippe Lacroix",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Brussel",
    "is_associated": false
  },
  "act_meta": {
    "language": "nl",
    "pub_date": "2018-02-27",
    "filing_date": "2018-02-13",
    "act_kind_objet": "Neerlegging van een fusievoorstel, opgesteld overeenkomstig artikel 693"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2018-02-13",
    "unanimous": null
  },
  "conversion": null,
  "detected_kind": "merger_absorption",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0425.353.116",
        "name": "Pharma Belgium",
        "role": "acquiring",
        "address": "Schumanplein 6 Bus 5, 1040 Brussel",
        "is_foreign": false,
        "legal_form": "Naamloze vennootschap",
        "is_new_company": false,
        "jurisdiction_country": null
      },
      {
        "kbo": "0404.182.964",
        "name": "Belmedis",
        "role": "absorbed",
        "address": "Congresstraat 35, 1000 Brussel",
        "is_foreign": false,
        "legal_form": "Naamloze vennootschap",
        "is_new_company": false,
        "jurisdiction_country": null
      }
    ],
    "exchange_ratio": 310.79,
    "legal_articles": [
      "12:7",
      "12:50",
      "693",
      "703"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": "2018-03-31",
    "exchange_ratio_text": "310,79 aandeel Pharma Belgium per 1 aandeel Belmedis",
    "new_shares_issued_n": 7094714,
    "real_estate_included": true,
    "patrimony_description": "Het gehele vermogen van Belmedis, zowel actief als passief, wordt overgenomen door Pharma Belgium. Dit omvat roerende en onroerende goederen, waaronder onroerende goederen in Gent, Antwerpen en Tessenderlo.",
    "equity_transferred_eur": null,
    "accounting_effective_date": "2018-04-01"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "Pharma Belgium",
    "legal_form": "Naamloze vennootschap"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Philippe Lacroix",
    "org_rep_person_name": null
  },
  "summary_narrative": "Pharma Belgium, een naamloze vennootschap met zetel in Brussel, heeft een fusievoorstel opgesteld overeenkomstig artikel 693 van het Wetboek Vennootschappen, met als doel de overname van Belmedis, een andere naamloze vennootschap met zetel in Brussel. De fusie zal plaatsvinden via overname van het gehele vermogen van Belmedis door Pharma Belgium, met een ruilverhouding van 310,79 aandelen Pharma Belgium per aandeel Belmedis. Er wordt geen geldelijke opleg gedaan; in plaats daarvan worden 7.094.714 nieuwe aandelen uitgegeven. De fusie wordt juridisch en boekhoudkundig vanaf 1 april 2018 geacht ",
  "co_filed_documents": [
    "fusievoorstel"
  ],
  "detected_real_type": "fusion_proposal",
  "referenced_correction": null,
  "should_reroute_to_category": null
}

{
  "stage": "proposal",
  "notary": {
    "name": "Philippe Lacroix",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2018-02-27",
    "filing_date": "2018-02-13",
    "act_kind_objet": ""
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2018-02-13",
    "unanimous": null
  },
  "conversion": null,
  "detected_kind": "merger_absorption",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0425.353.116",
        "name": "Pharma Belgium",
        "role": "acquiring",
        "address": "Rond-Point Schuman 6 bo\u00EEte 5, 1040 Bruxelles",
        "is_foreign": false,
        "legal_form": "SA",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      },
      {
        "kbo": "0404.182.964",
        "name": "Belmedis",
        "role": "absorbed",
        "address": "Rue du Congr\u00E8s 35, 1000 Bruxelles",
        "is_foreign": false,
        "legal_form": "SA",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      }
    ],
    "exchange_ratio": 310.79,
    "legal_articles": [
      "12:7",
      "12:50",
      "12:75",
      "12:103",
      "693 CS"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": "2018-04-01",
    "exchange_ratio_text": "310,79 actions Pharma Belgium pour 1 action Belmedis",
    "new_shares_issued_n": 7094714,
    "real_estate_included": true,
    "patrimony_description": "L\u0027ensemble du patrimoine actif et passif de Belmedis, y compris ses biens immobiliers situ\u00E9s \u00E0 Gent (Drongen), Antwerpen (Hoboken) et Tessenderlo, est transf\u00E9r\u00E9 \u00E0 Pharma Belgium.",
    "equity_transferred_eur": null,
    "accounting_effective_date": "2018-04-01"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "Pharma Belgium",
    "legal_form": "SA"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Philippe Lacroix",
    "org_rep_person_name": null
  },
  "summary_narrative": "Le 13 f\u00E9vrier 2018, un projet de fusion par absorption a \u00E9t\u00E9 \u00E9tabli entre la soci\u00E9t\u00E9 anonyme Pharma Belgium, soci\u00E9t\u00E9 absorbante, et Belmedis, soci\u00E9t\u00E9 absorb\u00E9e. Pharma Belgium recevra l\u0027int\u00E9gralit\u00E9 du patrimoine de Belmedis, y compris ses biens immobiliers en Flandre. Le rapport d\u0027\u00E9change est fix\u00E9 \u00E0 310,79 actions de Pharma Belgium pour une action de Belmedis, entra\u00EEnant l\u0027\u00E9mission de 7 094 714 nouvelles actions. La fusion prendra effet comptablement \u00E0 partir du 1er avril 2018.",
  "co_filed_documents": [
    "le projet de fusion"
  ],
  "detected_real_type": "fusion_proposal",
  "referenced_correction": null,
  "should_reroute_to_category": null
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "administrateur d\u00E9l\u00E9gu\u00E9",
      "person": {
        "rrn": null,
        "name": "Philippe Lacroix",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "commissaire",
      "person": {
        "rrn": null,
        "name": "Deloitte Bedrijfsrevisoren/R\u00E9viseurs d\u0027entreprises SC SPRL",
        "address": null,
        "birth_date": null
      }
    },
    {
      "kind": "director_in",
      "role": "administrateur",
      "person": {
        "rrn": null,
        "name": "Hubert Olivier",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0425.353.116",
    "name_full": "PHARMA BELGIUM"
  }
}